The molecular make-up of a tumour: Proteomics in cancer research

Clinical Science

Volumn 108, Issue 5, 2005, Pages 369-383

  Kolch, Walter ^a,b   Mischak, Harald ^c,d   Pitt, Andrew R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MOSAIQUES DIAGNOSTICS GMBH   (Germany)

Author keywords

Cancer research; Electrophoresis; Expression profiling; Mass spectromtery (MS); Proteomics; Tumour

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BIOLOGICAL MARKER; BISINDOLYLMALEIMIDE; CANCER ANTIBODY; IMATINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; RAPAMYCIN;

BIOINFORMATICS; BIOTECHNOLOGY; CANCER RESEARCH; CAPILLARY ELECTROPHORESIS; CHROMATOGRAPHY; IMMUNE RESPONSE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION PROFILING; HUMANS; MASS SPECTROMETRY; NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 18844445319     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20050006     Document Type: Review

References (126)

1. Steen, H. and Mann, M. (2004) The ABC's (and XYZ's) of peptide sequencing. Nat. Rev. Mol. Cell Biol. 5, 699-711
2. Hanash, S. M. (2000) Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 21, 1202-1209
3. Hondermarck, H. (2003) Breast cancer: when proteomics challenges biological complexity. Mol. Cell. Proteomics 2, 281-291
4. Dwek, M. V. and Alaiya, A. A. (2003) Proteome analysis enables separate clustering of normal breast, benign breast and breast cancer tissues. Br. J. Cancer 89, 305-307
5. Adam, P. J., Boyd, R., Tyson, K. L. et al. (2003) Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J. Biol. Chem. 278, 6482-6489
6. Van den, B. G. and Arckens, L. (2004) Fluorescent two-dimensional difference gel electrophoresis unveils the potential of gel-based proteomics. Curr. Opin. Biotechnol. 15, 38-43
7. Friedman, D. B., Hill, S., Keller, J. W. et al. (2004) Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4, 793-811
8. Somiari, R. I., Sullivan, A., Russell, S. et al. (2003) High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3, 1863-1873
9. Gorg, A., Obermaier, C., Boguth, G. et al. (2000) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21, 1037-1053
10. Huber, L. A., Pfaller, K. and Vietor, I. (2003) Organelle proteomics: implications for subcellular fractionation in proteomics. Circ. Res. 92, 962-968
11. Foster, L. J., de Hoog, C. L. and Mann, M. (2003) Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc. Natl. Acad. Sci. U.S.A. 100, 5813-5818
12. Oh, P., Li, Y., Yu, J. et al. (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (London) 429, 629-635
13. Essler, M. and Ruoslahti, E. (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U.S.A. 99, 2252-2257
14. Maeda, H., Fang, J., Inutsuka, T. and Kitamoto, Y. (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328
15. Hu, N., Flaig, M. J., Su, H. et al. (2004) Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma. Clin. Cancer Res. 10, 6013-6022
16. Shen, D., Chang, H. R., Chen, Z. et al. (2005) Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem. Biophys. Res. Commun. 326, 218-227
17. Garcia Pedrero, J. M., Fernandez, M. P., Morgan, R. O. et al. (2004) Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am. J. Pathol. 164, 73-79
18. Smitherman, A. B., Mohler, J. L., Maygarden, S. J. and Ornstein, D. K. (2004) Expression of annexin I, II and VII proteins in androgen stimulated and recurrent prostate cancer. J. Urol. 171, 916-920
19. Bai, X. F., Ni, X. G., Zhao, P. et al. (2004) Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J. Gastroenterol. 10, 1466-1470
20. Melle, C., Ernst, G., Schimmel, B. et al. (2004) A technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res. 64, 4099-4104
21. Kondo, T., Seike, M., Mori, Y., Fujii, K., Yamada, T. and Hirohashi, S. (2003) Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics 3, 1758-1766
22. Molloy, M. P. (2000) Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal. Biochem. 280, 1-10
23. Wu, C. C. and Yates, III, J. R. (2003) The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 21, 262-267
24. Gygi, S. P., Rist, B., Griffin, T. J., Eng, J. and Aebersold, R. (2002) Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J. Proteome Res. 1, 47-54
25. Han, D. K., Eng, J., Zhou, H. and Aebersold, R. (2001) Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 19, 946-951
26. Li, C., Hong, Y., Tan, Y. X. et al. (2004) Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell Proteomics 3, 399-409
27. Espina, V., Woodhouse, E. C., Wulfkuhle, J., Asmussen, H. D., Petricoin, III, E. F. and Liotta, L. A. (2004) Protein microarray detection strategies: focus on direct detection technologies. J. Immunol. Methods 290, 121-133
28. Liotta, L. A., Espina, V., Mehta, A. I. et al. (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317-325
29. Hudelist, G., Pacher-Zavisin, M., Singer, C. F. et al. (2004) Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res. Treat. 86, 281-291
30. Wulfkuhle, J. D., Aquino, J. A., Calvert, V. S. et al. (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3, 2085-2090
31. Liotta, L. A., Espina, V., Mehta, A. I. et al. (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317-325
32. Fodde, R., Smits, R. and Clevers, H. (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 1, 55-67
33. Walhout, A. J. and Vidal, M. (2001) Protein interaction maps for model organisms. Nat. Rev. Mol. Cell Biol. 2, 55-62
34. Colland, F., Jacq, X., Trouplin, V. et al. (2004) Functional proteomics mapping of a human signaling pathway. Genome Res. 14, 1324-1332
35. Blagoev, B., Kratchmarova, I., Ong, S. E., Nielsen, M., Foster, L. J. and Mann, M. (2003) A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 21, 315-318
36. Dziembowski, A. and Seraphin, B. (2004) Recent developments in the analysis of protein complexes. FEBS Lett. 556, 1-6
37. Verrier, F., Deniaud, A., Lebras, M. et al. (2004) Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis. Oncogene 23, 8049-8064
38. Eustace, B. K., Sakurai, T., Stewart, J. K. et al. (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 6, 507-514
39. Areces, L. B., Matafora, V. and Bachi, A. (2004) Analysis of protein phosphorylation by mass spectrometry. Eur. J. Mass Spectrom. 10, 383-392
40. Salih, E. (2004) Phosphoproteomics by mass spectrometry and classical protein chemistry approaches. Mass Spectrom. Rev., DOI 10.1002/mas.20042
41. Ficarro, S. B., McCleland, M. L., Stukenberg, P. T. et al. (2002) Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat. Biotechnol. 20, 301-305
42. Stensballe, A. and Jensen, O. N. (2004) Phosphoric acid enhances the performance of Fe(III) affinity chromatography and matrix-assisted laser desorption/ionization tandem mass spectrometry for recovery, detection and sequencing of phosphopeptides. Rapid Commun. Mass Spectrom. 18, 1721-1730
43. Jin, W. H., Dai, J., Zhou, H., Xia, Q. C., Zou, H. F. and Zeng, R. (2004) Phosphoproteome analysis of mouse liver using immobilized metal affinity purification and linear ion trap mass spectrometry. Rapid Commun. Mass Spectrom. 18, 2169-2176
44. Goshe, M. B., Veenstra, T. D., Panisko, E. A., Conrads, T. P., Angell, N. H. and Smith, R. D. (2002) Phosphoprotein isotope-coded affinity tags: application to the enrichment and identification of low-abundance phosphoproteins. Anal. Chem. 74, 607-616
45. Knight, Z. A., Schilling, B., Row, R. H., Kenski, D. M., Gibson, B. W. and Shokat, K. M. (2003) Phosphospecific proteolysis for mapping sites of protein phosphorylation. Nat. Biotechnol. 21, 1047-1054
46. Steinberg, T. H., Agnew, B. J., Gee, K. R. et al. (2003) Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics 3, 1128-1144
47. Schulenberg, B., Beechem, J. M. and Patton, W. F. (2003) Mapping glycosylation changes related to cancer using the Multiplexed Proteomics technology: a protein differential display approach. J. Chromatogr. B., Analyt. Technol. Biomed. Life Sci. 793, 127-139
48. Orth, A. P., Batalov, S., Perrone, M. and Chanda, S. K. (2004) The promise of genomics to identify novel therapeutic targets. Expert Opin. Ther. Targets 8, 587-596
49. Kramer, R. and Cohen, D. (2004) Functional genomics to new drug targets. Nat. Rev. Drug Discov. 3, 965-972
50. Godl, K., Wissing, J., Kurtenbach, A. et al. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 100, 15434-15439
51. Brehmer, D., Godl, K., Zech, B., Wissing, J. and Daub, H. (2004) Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol. Cell Proteomics 3, 490-500
52. Peggs, K. (2004) Imatinib mesylate: gold standards and silver linings. Clin. Exp. Med. 4, 1-9
53. Wissing, J., Godl, K., Brehmer, D. et al. (2004) Chemical proteomic analysis reveals alternative modes of action for pyrido[2, 3-d]pyrimidine kinase inhibitors. Mol. Cell Proteomics 3, 1181-1193
54. Parmar, S., Katsoulidis, E., Verma, A. et al. (2004) Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J. Biol. Chem. 279, 25345-25352
55. Mayer, I. A., Verma, A., Grumbach, I. M. et al. (2001) The p38 MAPK pathway mediates the growth inhibitory effects of interferon-α in BCR-ABL-expressing cells. J. Biol. Chem. 276, 28570-28577
56. Huang, J., Zhu, H., Haggarty, S. J. et al. (2004) Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U.S.A. 101, 16594-16599
57. Juan, H. F., Chen, J. H., Hsu, W. T. et al. (2004) Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4, 2766-2775
58. Ball, G., Mian, S., Holding, F. et al. (2002) An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18, 395-404
59. Qu, Y., Adam, B. L., Yasui, Y. et al. (2002) Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48, 1835-1843
60. Vlahou, A., Schorge, J. O., Gregory, B. W. and Coleman, R. L. (2003) Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol. 2003, 308-314
61. Wagner, M., Naik, D. N., Pothen, A. et al. (2004) Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 5, 26
62. Wittke, S., Fliser, D., Haubitz, M. et al. (2003) Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J. Chromatogr. A 1013, 173-181
63. Rogers, M. A., Clarke, P., Noble, J. et al. (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 63, 6971-6983
64. Petricoin, E. F., Ardekani, A. M., Hitt, B. A. et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577
65. Kolch, W., Mischak, H., Chalmers, M. J., Pitt, A. and Marshall, A. G. (2004) Clinical proteomics: a question of technology. Rapid Commun. Mass Spectrom. 18, 2365-2366
66. Anderson, N. L. and Anderson, N. G. (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 1, 845-867
67. Kolch, W., Neusüß, C., Pelzing, M. and Mischak, H. (2005) Capillary electrophoresis: mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev., DOI 10.1002/mas.20051
68. Tang, N., Tornatore, P. and Weinberger, S. R. (2004) Current developments in SELDI affinity technology. Mass Spectrom. Rev. 23, 34-44
69. Yip, T. T. and Lomas, L. (2002) SELDI ProteinChip array in oncoproteomic research. Technol. Cancer Res Treat. 1, 273-280
70. Ahram, M., Best, C. J., Flaig, M. J. et al. (2002) Proteomic analysis of human prostate cancer. Mol. Carcinog. 33, 9-15
71. Grizzle, W. E., Adam, B. L., Bigbee, W. L. et al. (2003) Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis. Markers 19, 185-195
72. Stevens, E. V., Liotta, L. A. and Kohn, E. C. (2003) Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int. J. Gynecol. Cancer 13 (Suppl. 2), 133-139
73. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y. and Chan, D. W. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304
74. Xiao, X., Liu, D., Tang, Y. et al. (2003) Development of proteomic patterns for detecting lung cancer. Dis. Markers 19, 33-39
75. Zhukov, T. A., Johanson, R. A., Cantor, A. B., Clark, R. A. and Tockman, M. S. (2003) Discovery of distinct protein profiles specific for lung tumors and premalignant lung lesions by SELDI mass spectrometry. Lung Cancer 40, 267-279
76. Tolson, J., Bogumil, R., Brunst, E. et al. (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid α in renal cancer patients. Lab. Invest. 84, 845-856
77. Zhang, Y. F., Wu, D. L., Guan, M. et al. (2004) Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin. Biochem. 37, 772-779
78. Koopmann, J., Zhang, Z., White, N. et al. (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res 10, 860-868
79. Paradis, V., Degos, F., Dargere, D. et al. (2004) Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41, 40-47
80. Krieg, R. C., Fogt, F., Braunschweig, T., Herrmann, P. C., Wollscheidt, V. and Wellmann, A. (2004) ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res. 24, 1791-1796
81. Yang, E. C., Guo, J., Diehl, G. et al. (2004) Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10. J. Proteome. Res. 3, 636-643
82. Wong, Y. F., Cheung, T. H., Lo, K. W. et al. (2004) Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett. 211, 227-234
83. Wilson, L. L., Tran, L., Morton, D. L. and Hoon, D. S. (2004) Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. N.Y. Acad. Sci. U.S.A. 1022, 317-322
84. Lin, Z., Jenson, S. D., Lim, M. S. and Elenitoba-Johnson, K. S. (2004) Application of SELDI-TOF mass spectrometry for the identification of differentially expressed proteins in transformed follicular lymphoma. Mod. Pathol. 17, 670-678
85. Laronga, C., Becker, S., Watson, P. et al. (2003) SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis. Markers 19, 229-238
86. Pusztai, L., Gregory, B. W., Baggerly, K. A. et al. (2004) Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100, 1814-1822
87. Wright, Jr, G. L., Cazares, L. H., Leung, S. M. et al. (1999) Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic. Dis. 2, 264-276
88. Melle, C., Kaufmann, R., Hommann, M. et al. (2004) Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. Int. J. Oncol. 24, 885-891
89. Kwapiszewska, G., Meyer, M., Bogumil, R. et al. (2004) Identification of proteins in laser-microdissected small cell numbers by SELDI-TOF and Tandem MS. BMC Biotechnol. 4, 30
90. Baggerly, K. A., Morris, J. S. and Coombes, K. R. (2004) Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20, 777-785
91. McDonald, W. H. and Yates, III, J. R. (2002) Shotgun proteomics and biomarker discovery. Dis. Markers 18, 99-105
92. Hamler, R. L., Zhu, K., Buchanan, N. S. et al. (2004) A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 4, 562-577
93. Wang, H., Kachman, M. T., Schwartz, D. R., Cho, K. R. and Lubman, D. M. (2002) A protein molecular weight map of ES2 clear cell ovarian carcinoma cells using a two-dimensional liquid separations/mass mapping technique. Electrophoresis 23, 3168-3181
94. Kreunin, P., Urquidi, V., Lubman, D. M. and Goodison, S. (2004) Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics 4, 2754-2765
95. Mischak, H., Kaiser, T., Walden, M. et al. (2004) Proteomic analysis for assessment of diabetic renal damage in humans. Clin. Sci. 107, 485-495
96. Kaiser, T., Kamal, H., Rank, A. et al. (2004) Proteomics applied to the clinical follow up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104, 340-349
97. Chaurand, P., Sanders, M. E., Jensen, R. A. and Caprioli, R. M. (2004) Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am. J. Pathol. 165, 1057-1068
98. Yanagisawa, K., Shyr, Y., Xu, B. J. et al. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362, 433-439
99. Schwartz, S. A., Weil, R. J., Johnson, M. D., Toms, S. A. and Caprioli, R. M. (2004) Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin. Cancer Res. 10, 981-987
100. Reyzer, M. L., Caldwell, R. L., Dugger, T. C. et al. (2004) Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res. 64, 9093-9100
101. Thun, M. J., Henley, S. J. and Gansler, T. (2004) Inflammation and cancer: an epidemiological perspective. Novartis Found. Symp. 256, 6-21
102. Blankenstein, T. (2004) The role of inflammation in tumour growth and tumour suppression. Novartis Found. Symp. 256, 205-210
103. Nadler, L. M. and Schultze, J. L. (2002) From genomics to cancer vaccines: patient-tailored or universal vaccines? Curr. Opin. Mol. Ther. 4, 572-576
104. Adam, G. C., Sorensen, E. J. and Cravatt, B. F. (2002) Trifunctional chemical probes for the consolidated detection and identification of enzyme activities from complex proteomes. Mol. Cell. Proteomics 1, 828-835
105. Admon, A., Barnea, E. and Ziv, T. (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2, 388-398
106. Hickman, H. D., Batson, C. L., Prilliman, K. R., Crawford, D. L., Jackson, K. L. and Hildebrand, W. H. (2000) C-terminal epitope tagging facilitates comparative ligand mapping from MHC class I positive cells. Hum. Immunol. 61, 1339-1346
107. Buchsbaum, S., Barnea, E., Dassau, L., Beer, I., Milner, E. and Admon, A. (2003) Large-scale analysis of HLA peptides presented by HLA-Cw4. Immunogenetics 55, 172-176
108. Prilliman, K., Lindsey, M., Zuo, Y., Jackson, K. W., Zhang, Y. and Hildebrand, W. (1997) Large-scale production of class I bound peptides: assigning a signature to HLA-B*1501. Immunogenetics 45, 379-385
109. Hunt, D. F., Henderson, R. A., Shabanowitz, J. et al. (1992) Characterization of peptides bound to the class I MHC molecule HLA-A2. 1 by mass spectrometry. Science 255, 1261-1263
110. Clark, R. E., Dodi, I. A., Hill, S. C. et al. (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98, 2887-2893
111. Singh-Jasuja, H., Emmerich, N. P. and Rammensee, H. G. (2004) The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunotner. 53, 187-195
112. Weinschenk, T., Gouttefangeas, C., Schirle, M. et al. (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818-5827
113. Lemmel, C., Weik, S., Eberle, U. et al. (2004) Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22, 450-454
114. Tureci, O., Usener, D., Schneider, S. and Sahin, U. (2005) Identification of tumor-associated autoantigens with SEREX. Methods Mol. Med. 109, 137-154
115. Imafuku, Y., Omenn, G. S. and Hanash, S. (2004) Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis. Markers 20, 149-153
116. Hong, S. H., Misek, D. E., Wang, H. et al. (2004) An autoantibody- mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res. 64, 5504-5510
117. Unwin, R. D., Harnden, P., Pappin, D. et al. (2003) Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 3, 45-55
118. Brichory, F., Beer, D., Le Naour, F., Giordano, T. and Hanash, S. (2001) Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 61, 7908-7912
119. Le Naour, F., Misek, D. E., Krause, M. C. et al. (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 7, 3328-3335
120. Shalhoub, P., Kern, S., Girard, S. and Beretta, L. (2001) Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis. Markers 17, 217-223
121. Gires, O., Munz, M., Schaffrik, M. et al. (2004) Profile identification of disease-associated humoral antigens using AMIDA, a novel proteomics-based technology. Cell. Mol. Life Sci. 61, 1198-1207
122. Nam, M. J., Madoz-Gurpide, J., Wang, H. et al. (2003) Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3, 2108-2115
123. Zhang, J., Li, Q., Nguyen, T. D. et al. (2004) A pentavalent single-domain antibody approach to tumor antigen discovery and the development of novel proteomics reagents. J. Mol. Biol. 341, 161-169
124. Liu, B., Conrad, F., Cooperberg, M. R., Kirpotin, D. B. and Marks, J. D. (2004) Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res. 64, 704-710
125. Petricoin, E. F., Fishman, D. A., Conrads, T. P., Veenstra, T. D. and Liotta, L. A. (2004) Lessons from Kitty Hawk: from feasibility to routine clinical use for the field of proteomic pattern diagnostics. Proteomics 4, 2357-2360
126. Taylor, C. F., Paton, N. W., Garwood, K. L. et al. (2003) A systematic approach to modeling, capturing, and disseminating proteomics experimental data. Nat. Biotechnol. 21, 247-254